Golden
Exosome Diagnostics

Exosome Diagnostics

A company developing and commercializing cancer molecular diagnostics based isolation of exosomes from body fluids. Exosome Diagnostics was founded in 2008.

Exosome Diagnostics isolates exosomes, cell-derived vesicles, which contain RNA, DNA and proteins, from serum, plasma, urine, cerebralspinal fluid and saliva. The company performs molecular analysis of exosomes for diagnotics, disease detection, treatment and monitoring. Exosome Diagnostics collaborates with pharmaceutical companies such as Amgen and Takeda in research and development, biomarker discovery, validation and development of diagnostics.

While Chief Scientific Officer Johan Skog was at Massachusetts General Hospital, he was the first to demonstrate the detection of molecular mutations in a tumor in RNA extracted from exosomes in Nature Cell Biology in 2008.

Timeline

March 2014

Exosome Diagnostics raises a $27,000,000 series B round from CD-Venture, Arcus Ventures, Qiagen, Tiger Management Corp., Monashee Capital Corp, NGN Capital and Forbion Capital Partners.

June 11, 2013

Exosome Diagnostics raises a $6,500,000 series B round.

May 11, 2010

Exosome Diagnostics raises a $20,000,000 series A round from Forbion Capital Partners.

2008

Exosome Diagnostics was founded.

People

Name
Role
LinkedIn

Johan Skog

Founding Scientist, CSO

John Healy

Employee

Mikkel Noerholm, PhD

VP Product Development

Thomas McLain, MBA, CPA

General Manager

William J. Kelly, CPA

CFO

Further reading

Title
Author
Link
Type
Date
+ Add new row

Documentaries, videos and podcasts

Title
Date
Link
+ Add new row

Companies

Company
CEO
Location
Products/Services
+ Add new row

References